Literature DB >> 29303221

The use of sonographic subjective tumor assessment, IOTA logistic regression model 1, IOTA Simple Rules and GI-RADS system in the preoperative prediction of malignancy in women with adnexal masses.

Jarosław Koneczny1, Artur Czekierdowski, Marek Florczak, Paweł Poziemski, Norbert Stachowicz, Dariusz Borowski.   

Abstract

BACKGROUND: Sonography based methods with various tumor markers are currently used to discriminate the type of adnexal masses.
OBJECTIVE: To compare the predictive value of selected sonography-based models along with subjective assessment in ovarian cancer prediction.
MATERIAL AND METHODS: We analyzed data of 271 women operated because of adnexal masses. All masses were verified by histological examination. Preoperative sonography was performed in all patients and various predictive models includ¬ing IOTA group logistic regression model LR1 (LR1), IOTA simple ultrasound-based rules by IOTA (SR), GI-RADS and risk of malignancy index (RMI3) were used. ROC curves were constructed and respective AUC's with 95% CI's were compared.
RESULTS: Of 271 masses 78 proved to be malignant including 6 borderline tumors. LR1 had sensitivity of 91.0%, specificity of 91.2%, AUC = 0.95 (95% CI: 0.92-0.98). Sensitivity for GI-RADS for 271 patients was 88.5% with specificity of 85% and AUC = 0.91 (95% CI: 0.88-0.95). Subjective assessment yielded sensitivity and specificity of 85.9% and 96.9%, respectively with AUC = 0.97 (95% CI: 0.94-0.99). SR were applicable in 236 masses and had sensitivity of 90.6% with specificity of 95.3% and AUC = 0.93 (95% CI 0.89-0.97). RMI3 was calculated only in 104 women who had CA125 available and had sensitivity of 55.3%, specificity of 94% and AUC = 0.85 (95% CI: 0.77-0.93).
CONCLUSIONS: Although subjective assessment by the ultrasound expert remains the best current method of adnexal tumors preoperative discrimination, the simplicity and high predictive value favor the IOTA SR method, and when not applicable, the IOTA LR1 or GI-RADS models to be primarily and effectively used.

Entities:  

Keywords:  GI-RADS model; IOTA group; LR1 model; RMI model; Simple Rules; ovarian cancer prediction; sonography

Mesh:

Year:  2017        PMID: 29303221     DOI: 10.5603/GP.a2017.0116

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  5 in total

1.  Diagnostic value of the gynecology imaging reporting and data system (GI-RADS) with the ovarian malignancy marker CA-125 in preoperative adnexal tumor assessment.

Authors:  Michal Migda; Migda Bartosz; Marian S Migda; Marcin Kierszk; Gieryn Katarzyna; Marek Maleńczyk
Journal:  J Ovarian Res       Date:  2018-11-03       Impact factor: 4.234

2.  Sonographic Assessment of Complex Ultrasound Morphology Adnexal Tumors in Pregnant Women with the Use of IOTA Simple Rules Risk and ADNEX Scoring Systems

Authors:  Artur Czekierdowski; Norbert Stachowicz; Agata Smoleń; Tomasz Kluz; Tomasz Łoziński; Andrzej Miturski; Janusz Kraczkowski
Journal:  Diagnostics (Basel)       Date:  2021-02-28

3.  The diagnostic performance of the Gynecologic Imaging Reporting and Data System (GI-RADS) in adnexal masses.

Authors:  Wen Guo; Xiuhe Zou; Hanyue Xu; Tao Zhang; Yunuo Zhao; Lu Gao; Wenyue Duan; Xuelei Ma; Ling Zhang
Journal:  Ann Transl Med       Date:  2021-03

4.  A comparison of the diagnostic performance of the O-RADS, RMI4, IOTA LR2, and IOTA SR systems by senior and junior doctors.

Authors:  Yuyang Guo; Baihua Zhao; Shan Zhou; Lieming Wen; Jieyu Liu; Yaqian Fu; Fang Xu; Minghui Liu
Journal:  Ultrasonography       Date:  2022-01-31

Review 5.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.